A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
About this clinical trial
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.
At a glance
What medical conditions are being studied?
What is the clinical trial testing?
Placebo, TAK-279
How many participants are being enrolled?
268
Are placebos part of the clinical trial?
Yes
When is the clinical trial being conducted?
Mar 2024 - Jul 2027
How long is participation in the clinical trial?
Participants can be in this study for up to 56 weeks (1 year and 1 month).
Key requirements
Sexes
All
Age
18 to 75 Years
Healthy volunteers?
No
Entry criteria
